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Malaria parasite infections that are only detectable bymolecularmethods are highly prevalent and represent a potential transmission
reservoir. Themethods used to detect these infections are not standardized, and their operating characteristics are often unknown.We
designed a proficiency panel ofPlasmodium spp. in order to compare the accuracy of parasite detection of molecular protocols
used by labs in a clinical trial consortium. Ten dried blood spots (DBSs) were assembled that contained P. falciparum, P. vivax,
P. malariae, and P. ovale; DBSs contained either a single species or a species mixed with P. falciparum. DBS panels were tested
in 9 participating laboratories in a masked fashion. Of 90 tests, 68 (75.6%) were correct; there were 20 false-negative results and 2
false positives. The detection rate was 77.8% (49/63) for P. falciparum, 91.7% (11/12) for P. vivax, 83.3% (10/12) for P. malariae,
and 70% (7/10) for P. ovale. Most false-negative P. falciparum results were from samples with an estimated<5 parasites perl
of blood. Between labs, accuracy ranged from 100% to 50%. In one lab, the inability to detect species in mixed-species infections
prompted a redesign and improvement of the assay. Most PCR-based protocols were able to detect P. falciparum and P. vivax at
higher densities, but these assays may not reliably detect parasites in samples with low P. falciparum densities. Accordingly, for-
mal quality assurance for PCR should be employed whenever this method is used for diagnosis or surveillance. Such efforts will
be important if PCR is to be widely employed to assist malaria elimination efforts.
Molecular detection methods for malaria parasites, includ-ing PCR assays, detect low-level malaria parasitemias that
are missed by microscopy and rapid diagnostic tests (RDTs). In
many settings, these “submicroscopic” infections usually far
outnumber patent infections (1). Because they are not identi-
fied by routine clinical or research diagnostics and therefore
remain untreated, they constitute a reservoir of parasites for
ongoing transmission (2). Thus, efforts to reduce transmission
and eliminate malaria may need to use PCR in order to elimi-
nate the malaria reservoir (3).
PCR-based methods to detect malaria parasites are diverse in
design and operation. These factors have the potential to intro-
duce substantial variability in the operating characteristics of
methods (4). The definition of “submicroscopic” parasites is fur-
ther complicated by inconsistencies between operators in assess-
ing parasites by microscopy (5). Collectively, these microscopic
and molecular considerations can produce inconsistencies in
measurement and undermine the generalizability of findings re-
lated to PCR-detectable parasites.
Quality control procedures have been endorsed by the WHO for
parasite detection by both microscopy (6) and RDTs (7), likely owing
to their clinical use. Although RDTs have been advanced as adequate
tools to capture the submicroscopic parasite reservoir (8), their sen-
sitivity of parasite detection is generally lower than that achieved by
PCR methods or by expert microscopy (9). Therefore, PCR methods
are increasingly employed for parasite detection in research studies,
and there exist nascent efforts to standardize quantification (10) and
reporting (11) of assays. Nevertheless, the comparative, qualitative
performance of PCR assays used to detect the major species of malaria
parasites is largely unknown.
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The Malaria in Pregnancy Consortium is a global consortium
of research groups conducting clinical studies investigating the
impacts of current and novel interventions to prevent pregnancy-
associated malaria (http://www.mip-consortium.org/). Two fac-
tors necessitated the evaluation of PCR assays in this complex
clinical trial consortium: (i) the use of multiple laboratories with
various methodologies for molecular parasite detection, and (ii)
the requisite need to quantify the impact on birth outcomes of the
low-level parasitemias that are typically observed in pregnancy.
Therefore, we assembled a “proficiency panel” of Plasmodium
parasites and distributed this panel to associated molecular labo-
ratories for masked testing. Herein, we describe the design of the
panel and the results of testing at 9 molecular laboratories from
four continents.
MATERIALS AND METHODS
Panel design. A panel of 10 dried blood spots (DBSs) was designed that
contained the four most common human malaria parasites:P. falciparum,
P. vivax,P. ovale, andP.malariae. We designed the panel to address several
common issues with molecular detection methods: (i) the ability to detect
all four of the most common human malaria species in Africa; (ii) the
sensitivity of P. falciparum detection, taking into account three different
parasite densities (5%, 0.5%, and trace); (iii) the ability to discriminate
species within mixed-species infections that would most likely include P.
falciparum (thus, we included samples of each of the other species mixed
with P. falciparum).
Additionally, we included a DBS with uninfected whole blood as a
control. The sources of each parasite are summarized in Table 1.
Panel assembly. For DBSs with P. falciparum, P. falciparum line 3D7
(MRA-102, MR4; ATCC, Manassas, VA) was cultivated in continuous in
vitro culture in O human red blood cells (RBCs) to 5% to 13% parasite
density (as confirmed by light microscopy), centrifuged to remove serum
and concentrate RBCs, and split with uninfected fresh whole blood col-
lected in a tube with EDTA to obtain the targeted parasite densities. Be-
cause of variations in the density of cultivated parasites and hematocrits,
varied final densities of P. falciparum 3D7 were considered approximate.
For DBSs with P. falciparummixed with other species, P. vivax, P. ovale, or
P. malariae was added to the 3D7 aliquot.
For P. vivax, a 500-l specimen of 40,000 parasites/l at 50% hemat-
ocrit was used. This was diluted with fresh uninfected whole blood with or
without additional P. falciparum strain 3D7 from culture to obtain P.
vivax-containing DBSs. For P. malariae and P. ovale, we blotted fresh
venous blood from admitted patients onto filter paper, with or without
additional P. falciparum strain 3D7 from culture, to obtain DBSs.
All DBSs consisted of 50 l of blood aliquoted from the single prepa-
rations as described above. These were placed onto prelabeled Whatman
3MM filter paper in duplicate and left to air dry overnight. All DBSs were
produced in a laminar flow hood. The 10 DBSs that comprised each panel
were placed into a single sealable plastic bag with desiccant and separated
within by standard weighing paper.
Panel internal quality control. Genomic DNA (gDNA) was extracted
within 2 weeks of preparation and storage at 4°C from each DBS of a single
set of 10 DBSs after punching a 5-mm hole from each DBS by using a
QIAamp DNA minikit. gDNA samples were tested for P. falciparum, P.
malariae, P. ovale, and the human gene glyceraldehyde 3-phosphate de-
hydrogenase (gapdh), using duplex real-time PCR assays targeting the
Plasmodium 18S rRNA gene (12). Cycle thresholds (CT) were set manually
by personnel masked to input gDNA. Samples were also tested in a sepa-
rate SYBR green real-time PCR assay targeting only P. vivax (13); this 25
l reaction mixture consisted of 12.5 l of SYBR green master mix, 900
nM (each) primers targeting the P. vivax 18S rRNA, and 5 l of template.
In order to estimate the quantities of P. falciparum parasites in the
samples, gDNA samples were tested in a P. falciparum-specific real-time
PCR assay targeting the single-copy gene P. falciparum lactate dehydroge-
nase (Pfldh) (14). The reactions were performed with a set of 10 standards
of P. falciparum 3D7 gDNA from 0.1 ng/l to 5 105 ng/l, which were
used to generate a standard curve and estimate parasite quantities in the
unknowns.
All real-time PCRs were prepared in a laminar flow hood with filtered
pipette tips, tests were performed in duplicate, and samples were tested on
plates that included appropriate negative and positive controls.
Distribution of panels. We offered the panel to collaborating labora-
tories within the Malaria in Pregnancy Consortium and to others who
requested it. The panels were posted at room temperature and received
within 7 days of sending. Each filter paper was labeled only 1 to 10. A letter
accompanying the panel informed recipients of the following: “The sam-
ples represent P. falciparum, vivax, ovale, and malariae, some in mixed
fashion, and some as pure species. All samples were prepared with whole
parasites, so they should accommodate any genes targeted by your molec-
ular assays.” Therefore, recipients were blinded to the constituents of the
DBSs. The panels were tested per each laboratory’s standard procedures
for parasite detection.
Collaborating laboratories were located in Gambia, Benin, Gabon,
Kenya, Tanzania, Mozambique, India, The Netherlands, and Italy. After
the collaborating laboratory tested the panel, feedback was provided on
the accuracy of results to both the laboratory staff and the principal inves-
tigator of the associated clinical study. The detection rate was defined
as the number of correct species detected divided by the number of species
tested for; therefore, these rates were computed only for species that were
TABLE 1 Constituents of the proficiency panel
Sample Component(s)a
1 P. ovale from a patient admitted with microscopic P. ovale
2 P. falciparum strain 3D7 from culture (approximately 5%, or 4 106 parasites) added to P. malariae and trace P. falciparum from a
patient admitted with microscopic P. malariae (submicroscopic P. falciparum)
3 P. vivax strain Brazil I from an Aotus monkey (approximately 5 105 parasites)
4 Noninfected fresh whole blood
5 P. falciparum strain 3D7 from culture (approximately 5%, or 1.6 107 parasites)
6 P. falciparum strain 3D7 from culture (approximately 5%, or 9 106 parasites) and P. vivax strain Brazil I from an Aotus monkey
(approximately 5 105 parasites)
7 P. falciparum strain 3D7 from culture (approximately 5%, or 1.5 106 parasites) added to P. ovale from a patient admitted with
microscopic P. ovale
8 P. falciparum strain 3D7 from culture (trace, or 1.5 105 parasites)
9 P. falciparum strain 3D7 from culture (approximately 0.5%, or 2.6 105 parasites)
10 P. malariae and trace P. falciparum from a patient admitted with microscopic P. malariae (submicroscopic P. falciparum)
a All samples included whole blood, either from an infected patient (samples 1, 2, 7, and 10) or uninfected whole blood from a single donor (samples 3, 4, 5, 6, 8, and 9). Estimated
quantities of input 3D7 were computed from input parasitemias and output quantitation.
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targeted by the laboratory’s assay. False-positive results were defined as
the detection of a species that was absent; false-negative results were de-
fined as the failure to detect a species that was present.
Ethics statement. The collection and use of Plasmodium parasites
from patients at the University of North Carolina Hospital were approved
by the UNC Institutional Review Board.
RESULTS AND DISCUSSION
Panel assembly andquality control.We produced 20 panels of 10
DBSs each. The constituents of each panel are outlined in Table 1.
Internally, a panel was first tested with real-time PCR assays that
collectively detected all 4 Plasmodium species that are known to be
transmitted in Africa as well as a human gene. In this testing,
human DNA was detected in all 10 DBSs. All four species were
detected from each DBS on which they were known to be present,
in both mono- and mixed-species samples. The DBS with only
uninfected blood was positive only for the human control gene.
There were no false-positive results.
A second assay capable of estimating P. falciparum quantity
was also 100% sensitive and specific, although the two samples
containing “trace” P. falciparum returned discordant results be-
tween the two replicates. Based upon standard curves, this assay
returned quantity estimates of 0.5 parasites/l of gDNA (sample
8) and 2 parasites/l of gDNA (sample 10) for these two trace P.
falciparum samples. Because each DNA extraction yielded 50l of
gDNA from approximately 20l of blood, we estimated that these
samples contained approximately 1.25 and 5 parasites/l of whole
blood, respectively.
Results by Plasmodium species. We distributed the panel to 9
collaborating molecular laboratories for testing. The protocols
employed by these labs are outlined in Table 2. These laboratories
were blinded to the true constituents of each DBS. Overall, 68 of
90 (75.6%) results were correct (Table 3). Of the 22 incorrect
results, 20 were false-negative results and 2 were false positives.
The detection rate was 77.8% (49/63) for P. falciparum, 91.7%
(11/12) for P. vivax, 83.3% (10/12) for P. malariae, and 70% (7/
10) for P. ovale (Fig. 1). Among P. falciparum samples, the detec-
tion rate for P. falciparum was 77.8% both for monospecies sam-
ples (21/27) and for multispecies samples (28/36). Among P.
falciparum monospecies samples, the detection rate was 100%
(9/9) for those with 5% parasite density, 100% (9/9) for those with
0.5% density, and 33.3% (3/9) for those with trace parasites (Fig.
1). Therefore, overall, the diverse protocols employed were largely
able to accurately detect P. falciparum when present at densities
that are typically identified in clinical infections in monospecies
infections and when mixed with other Plasmodium spp.
Detection of P. falciparumwas reduced at the lowest density. In
the sample containing only trace amounts of P. falciparum from in
vitro culture, only 3/9 labs detected the parasite. Similarly, in the
sample with microscopically detected P. malariae and submicro-
scopic P. falciparum, only 1/9 labs detected P. falciparum. This low
detection rate (22.2%; 4/18) of trace P. falciparum suggests that
some PCR protocols require optimization to improve sensitivity
and that this sensitivity should be routinely quantified and re-
ported, as has been suggested for real-time PCR protocols (15).
Among P. vivax samples, the detection rate was 100% (6/6) for
monospecies P. vivax and 83.3% (5/6) for P. vivax when mixed
with P. falciparum. Only 6 of the 9 labs included methods to detect
P. vivax in their protocols. The only false-negative P. vivax result
originated from lab B, which failed to report any mixed infections. T
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After revising their workflow, both P. falciparum and P. vivaxwere
successfully detected. Therefore, the diverse protocols employed
in these labs were largely able to detect P. vivax in mono- and
mixed-species parasitemias.
P. ovale had the lowest detection rate of the four species (70%),
though it was assayed the least frequently, in only 10 tests. The
three false-negative results occurred in labs that reported other
false negatives; therefore, it is unclear if the errors resulted from
laboratory procedures or from an inability to detect the dimorphic
P. ovale (16).
There were only 2 false-positive results: one lab reported P.
falciparum in the negative DBS, and another lab reported P. fal-
ciparum in the P. vivax monospecies sample. Among the 20 false-
negative results, 14 resulted from the failure to detect P. falcipa-
rum in trace quantities either in a monospecies sample or mixed
with P. malariae.
Results by laboratory. Accuracy ranged from 100% (Lab A) to
50% (Labs B and F). In five of the labs (C, E, G, H, and J), the only
incorrect results were the failure to detect P. falciparum in trace
amounts, either alone or when mixed with P. malariae.
Detection of mixed infections was challenging. Lab B returned 5
incorrect results: one false positive (P. falciparum detected in an
uninfected sample) and four false negatives (all in mixed-species
infections). These results prompted discussions with the labora-
tory head and with a reference laboratory regarding the protocol
used. The real-time PCR protocol consisted of a single set of Plas-
modium primers multiplexed with four species-specific probes,
suggesting that, in mixed-species infections, only the dominant
species was being amplified and detected. This competitive inhi-
bition can reduce the sensitivity of parasite PCR assays (17). The
protocol was modified to include species-specific forward prim-
ers, and a fresh panel was retested with the updated protocol.
Using this updated protocol, the assay was newly able to detect P
vivax, P. ovale, and P. malariae when each was mixed with P.
falciparum, thus improving the assay’s ability to detect mixed in-
fections (Lab D). The updated protocol subsequently went live in
Labs B and D.
Future directions and recommendations. Our observations
suggest several practices that will help to assure high quality in
molecular detection protocols.
(i) A DBS panel of Plasmodium spp. should be tested and in-
terpreted by standard protocols by routine laboratory staff
blinded to sample constituents.
(ii) This testing should be repeated at planned intervals or
when procedures are altered by the addition of new reagents,
hardware, or personnel.
(iii) For protocols that are employed to detect low-level, “sub-
microscopic” parasitemias to aid in malaria elimination efforts,
the lower limit of detection of the assay should be formally quan-
tified and reported. This can be achieved by using a panel of P.
falciparum samples across a range of parasite densities.
PCR methods and laboratories vary in their sensitivities and
specificities to detect malaria parasites. Most protocols tested in
this study consistently detected the major species P. falciparum
and P. vivax at densities that typically manifest symptoms. How-
ever, sensitivities and specificities of P. falciparum detection were
much more variable for low-level and submicroscopic para-
sitemias. Submicroscopic infections are important because they
constitute reservoirs of parasites that can sustain transmission
(18) and are targeted by elimination campaigns (2). Additionally,
T
A
B
LE
3
R
esu
lts
of
m
olecu
lar
testin
g
of
th
e
profi
cien
cy
pan
elat
th
e
sou
rce
laboratory
an
d
9
collaboratin
g
laboratories
Lab
Species
targeted
Species
detected
w
h
en
sam
ple
con
tain
ed
a:
P
.ovale
P
.falciparum
(5%
)
an
d
P
.
m
alariae
P
.vivax
N
egative
P
.falciparum
(5%
)
P
.falciparum
(5%
)
an
d
P
.vivax
P
.falciparum
(5%
)
an
d
P
.ovale
P
.falciparum
(trace)
P
.falciparum
(0.5%
)
P
.falciparum
(trace)
an
d
P
.
m
alariae
U
N
C
P
.falciparum
,P
.vivax,
P
.m
alariae,P
.ovale
P
.ovale
P
.falciparum
an
d
P
.m
alariae
P
.vivax
N
egative
P
.falciparum
P
.falciparum
an
d
P
.vivax
P
.falciparum
an
d
P
.ovale
P
.falciparum
P
.falciparum
P
.falciparum
an
d
P
.m
alariae
U
N
C
P
.falciparum
N
egative
P
.falciparum
N
egative
N
egative
P
.falciparum
P
.falciparum
P
.falciparum
P
.falciparum
*
P
.falciparum
P
.falciparum
*
A
P
.falciparum
,P
.vivax,
P
.m
alariae
N
egative
P
.falciparum
an
d
P
.m
alariae
P
.vivax
N
egative
P
.falciparum
P
.falciparum
an
d
P
.vivax
P
.falciparum
P
.falciparum
P
.falciparum
P
.falciparum
an
d
P
.m
alariae
B
P
.falciparum
,P
.vivax,
P
.m
alariae,P
.ovale
P
.ovale
P
.
falciparu
m
P
.vivax
P
.falciparum
P
.falciparum
P
.
falciparu
m
P
.
falciparu
m
P
.falciparum
P
.falciparum
P
.
m
alariae
C
P
.falciparum
,P
.vivax,
P
.m
alariae,P
.ovale
P
.ovale
P
.falciparum
an
d
P
.m
alariae
P
.vivax
N
egative
P
.falciparum
P
.falciparum
an
d
P
.vivax
P
. falciparum
an
d
P
.ovale
N
egative
P
.falciparum
P
.
m
alariae
D
P
.falciparum
,P
.vivax,
P
.m
alariae,P
.ovale
P
.ovale
P
.falciparum
an
d
P
.m
alariae
P
.falciparum
an
d
P
.vivax
N
egative
P
.falciparum
P
.falciparum
an
d
P
.vivax
P
.falciparum
an
d
P
.ovale
N
egative
P
.falciparum
P
.
m
alariae
E
P
.falciparum
N
egative
P
.falciparum
N
egative
N
egative
P
.falciparum
P
.falciparum
P
.falciparum
N
egative
P
.falciparum
N
egative
F
P
.falciparum
,P
.vivax,
P
.m
alariae,P
.ovale
N
egative
P
.
falciparu
m
P
.vivax
N
egative
P
.falciparum
P
.falciparum
an
d
P
.vivax
P
.
falciparu
m
N
egative
P
.falciparum
P
.
m
alariae
G
P
.falciparum
N
egative
P
.falciparum
N
egative
N
egative
P
.falciparum
P
.falciparum
P
.falciparum
N
egative
P
.falciparum
N
egative
H
P
.falciparum
N
egative
P
.falciparum
N
egative
N
egative
P
.falciparum
P
.falciparum
P
.falciparum
P
.falciparum
*
P
.falciparum
N
egative
J
P
.falciparum
,P
.vivax,
P
.m
alariae,P
.ovale
P
.ovale
P
.falciparum
an
d
P
.m
alariae
P
.vivax
N
egative
P
.falciparum
P
.falciparum
an
d
P
.vivax
P
.falciparum
an
d
P
.ovale
N
egative
P
.falciparum
P
.
m
alariae
a
False-positive
resu
lts
are
sh
aded;false-n
egative
resu
lts
are
sh
ow
n
in
bold.*,on
e
oftw
o
replicates
w
as
positive
for
P
.falciparum
.
Plasmodium PCR Quality Control
June 2014 Volume 52 Number 6 jcm.asm.org 2147
 o
n
 June 11, 2014 by University of Liverpool Library
http://jcm.asm.org/
D
ow
nloaded from
 
quantitative PCR methods are increasingly used to measure par-
asite clearance in drug efficacy studies (19).
Our study had several limitations. First, we included a limited
number of strains of each species owing to restricted availability,
and genetic diversity of the targets could have produced false neg-
atives. Nevertheless, we did include reference standards of both P.
falciparum and P. vivax, and all assays used by collaborating labs
targeted common, conserved sequences and were previously val-
idated against multiple P. falciparum strains. Additionally, as
noted above, we included only a single P. ovale sample of indeter-
minate geographic origin, which may not reflect global species
diversity owing to the recent recognition of its dimorphism. Fi-
nally, with only 10 DBSs, we did not comprehensively test the
limits of detection and the quantitative performance of the assays.
Future efforts should include a greater range of parasite densities
to assist in defining this measure for molecular parasite assays.
In order to allow comparability between sites, PCR assays
should be subject to strict ongoing quality control programs. Such
efforts can utilize new panel preparations, such as those described
here, including preparations of parasites obtained from central
repositories, such as the Malaria Research and Reference Reagent
Resource Center (MR4) or a P. falciparum preparation available
through the UK National Institute for Biological Standards and
Control, which has been endorsed by the WHO as a standard
quantity of P. falciparum DNA (10). Notably, the WHO currently
sponsors external quality assurance programs for the molecular
detection of influenza virus (20) and HIV drug resistance muta-
tions (21). Similar centralized efforts may be required if molecular
detection assays for malaria parasites become increasingly vital for
malaria control programs.
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